The Role of Adenosine and Its Degradation Enzymes – Adenosinedeaminase and Adenosinekinase in Pathogenesis of Vasovagal Syncope

Lazurova, Zora; Mitro, Peter; Popovnakova, Marcela

doi:10.1016/j.ejim.2022.08.037

Cited by 4 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, there is evidence that an adenosinergic disturbance is implicated in NES. In vasovagal syncope: high basal APL was reported with a significant increase during the HUT associated with fainting [ 11 ], while an increase in APL was also reported during HUT [ 11 , 21 , 22 ]. This increase may explain the lack of prodromes in this patient population.…”

Section: Role Of the Adenosinergic System In Nesmentioning

confidence: 99%

“…This increase may explain the lack of prodromes in this patient population. The APL increase was much higher in patients with predominant vasodilation [ 21 ]. This is in agreement with the fact that the K D value for A 2A R is much higher (1.8 µM, [ 23 ]) than for A 1 R (0.8 µM, [ 24 ]).…”

Section: Role Of the Adenosinergic System In Nesmentioning

confidence: 99%

“…Indeed, in the case of high basal APL, A 1 R is mostly desensitized and only A 2A R could be activated [ 25 ]. The increase in basal APL may be explained by the decrease in ADA activity [ 21 ]. Furthermore, high A 2A R expression was reported in this patient population [ 26 , 27 ] while a specific SNP (c 1083 C > T) in the second exon of the gene encoding A 2A R was found [ 26 ] but not confirmed by others [ 27 ].…”

Section: Role Of the Adenosinergic System In Nesmentioning

confidence: 99%

See 2 more Smart Citations

Adenosinergic System and Neuroendocrine Syncope: What Is the Link?

Guieu

Fromonot

Mottola

et al. 2023

Cells

View full text Add to dashboard Cite

Although very common, the precise mechanisms that explain the symptomatology of neuroendocrine syncope (NES) remain poorly understood. This disease, which can be very incapacitating, manifests itself as a drop in blood pressure secondary to vasodilation and/or extreme slowing of heart rate. As studies continue, the involvement of the adenosinergic system is becoming increasingly evident. Adenosine, which is an ATP derivative, may be involved in a large number of cases. Adenosine acts on G protein-coupled receptors with seven transmembrane domains. A1 and A2A adenosine receptor dysfunction seem to be particularly implicated since the activation leads to severe bradycardia or vasodilation, respectively, two cardinal symptoms of NES. This mini-review aims to shed light on the links between dysfunction of the adenosinergic system and NHS. In particular, signal transduction pathways through the modulation of cAMP production and ion channels in relation to effects on the cardiovascular system are addressed. A better understanding of these mechanisms could guide the pharmacological development of new therapeutic approaches.

show abstract

Section: Role Of the Adenosinergic System In Nesmentioning

confidence: 99%

Section: Role Of the Adenosinergic System In Nesmentioning

confidence: 99%

Section: Role Of the Adenosinergic System In Nesmentioning

confidence: 99%

See 1 more Smart Citation

Adenosinergic System and Neuroendocrine Syncope: What Is the Link?

Guieu

Fromonot

Mottola

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…Additionally, there are novel lines of research based on translational research, which aim, through the identification of polymorphisms, to categorize the existence of phenotypes resistant or responsive to specific therapies, which would help to describe new pathophysiological mechanisms and to design new therapeutic targets (44)(45)(46)(47)(48)(49)(50). It can be stated that it is a current issue about which not much is known and on which the sociodemographic, clinical, and genotype characterization of the affected population depends greatly.…”

Section: Future Perspectivesmentioning

confidence: 99%

Utilidad de la midodrina para controlar el síncope vasovagal: ¿la recomienda la evidencia?

Picón-Jaimes,

Toro-Gómez,

Castillo-Restrepo

et al. 2023

Revista Investig. Salud Univ. Boyacá

View full text Add to dashboard Cite

Introducción: El síncope vasovagal es la principal causa de pérdida transitoria de la conciencia, y es un motivo de consulta cada vez más frecuente en pediatría y medicina del adulto. La midodrina es un agonista de los receptores alfa, de acción periférica, empleada principalmente en el manejo de la hipotensión ortostática; sin embargo, también se ha evaluado en el síncope vasovagal, con resultados prometedores. Objetivo: Analizar la evidencia más reciente sobre la utilidad de la midodrina para el control y la prevención del síncope vasovagal. Materiales y métodos: Se realizó una búsqueda bibliográfica utilizando términos de búsqueda como Vasovagal Syncope y Midodrine, así como sinónimos, que se combinaron con operadores booleanos, en cinco bases de datos, hasta octubre del 2022. Se incluyeron estudios originales, revisiones sistemá- ticas y metanálisis, publicados tanto en inglés como en español. Resultados: Ensayos controlados aleatorizados y revisiones sistemáticas y metanálisis difieren ligeramente entre resultados, pero estos demuestran un efecto global protector. La evidencia más reciente y completa indica que utilizar este agente reduce significativamente la positividad al realizar la prueba de la mesa inclinada y que previene la aparición de episodios sincopales. Conclusiones: Aunque la evidencia actual sobre la eficacia de la midodrina respecto a la prevención y control del síncope vasovagal es limitada, se observa un efecto protector significativo, porque disminuye el riesgo de sufrir un episodio sincopal, aproximadamente hasta en un 50%.

show abstract